Time to abandon microalbuminuria? - Ruggenenti, P.; Remuzzi, G. (Kidney international, 2006)
Keywords: Albuminuria - complications; Albuminuria - diagnosis; Albuminuria - etiology; angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - administration & dosage; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; autosomal dominant polycystic kidney disease; Biological and medical sciences; Biomarkers; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Chronic Disease; chronic renal disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - complications; Disease Progression; Endothelium, Vascular - physiopathology; Forecasting; Glomerular Filtration Rate; Humans; Insulin Resistance; Kidney Diseases - epidemiology; Kidney Diseases - prevention & control; Kidney Failure, Chronic - etiology; Kidney Failure, Chronic - prevention & control; Losartan - administration & dosage; Losartan - therapeutic use; Medical sciences; Metabolic Syndrome - complications; Metabolic Syndrome - urine; nephrology; Nephrology. Urinary tract diseases; Polycystic Kidney, Autosomal Dominant - epidemiology; Polycystic Kidney, Autosomal Dominant - prevention & control; Proteinuria - complications; Proteinuria - diagnosis; Proteinuria - etiology; Randomized Controlled Trials as Topic; Rats; Risk Factors; Terminology as Topic; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; nephrology; angiotensin-converting enzyme inhibitors; autosomal dominant polycystic kidney disease; chronic renal disease; Nephrology; Urinary system disease; Albumin; Time; Microalbuminuria; Urology; Proteinuria